Betamethasone Benzoate

CHEMBL1200376 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

496.6 g/mol

LogP

3.9

Phase

4

An ester form of betamethasone formulated for topical use to treat inflammatory skin conditions such as eczema and psoriasis. It reduces redness, itching, and swelling by suppressing local immune responses in the skin. Prolonged application to large skin areas or under occlusion increases the risk of systemic absorption.

Moleküler Ağırlık

496,6000 g/mol

LogP

3,90

TPSA

101,00 Å²

Lipinski RO5

Geçer

Etki Mekanizması

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccccc1)C(=O)CO

InChI

InChI=1S/C29H33FO6/c1-17-13-22-21-10-9-19-14-20(32)11-12-26(19,2)28(21,30)23(33)15-27(22,3)29(17,24(34)16-31)36-25(35)18-7-5-4-6-8-18/h4-8,11-12,14,17,21-23,31,33H,9-10,13,15-16H2,1-3H3/t17-,21-,22-,23-,26-,27-,28-,29-/m0/s1

Molecular Formula

C29H33FO6

HBD / HBA

2 / 7

Döndürülebilir Bağlar

5

Ağır Atomlar

36

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

An ester form of betamethasone formulated for topical use to treat inflammatory skin conditions such as eczema and psoriasis. It reduces redness, itching, and swelling by suppressing local immune responses in the skin. Prolonged application to large skin areas or under occlusion increases the risk of systemic absorption.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Betamethasone Benzoate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200376. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5282492. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Betamethasone Benzoate PillFYI'da

Yapı

Hızlı Veriler

Formül: C29H33FO6

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Betamethasone Benzoate

Etki Mekanizması

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

Sıkça Sorulan Sorular

References & Data Sources

Embed This Widget